© 2017 Elsevier B.V. Objective The Opiate Dosage Adequacy Scale (ODAS) is a clinical tool to individually measure the “adequacy” of opioid doses in patients on maintenance treatment. The aim of this paper is to provide evidence for the validity and reliability of the ODAS in a sample of patients in buprenorphine/naloxone (B/N) maintenance treatment. Method Cross-sectional study of a convenience sample of B/N-treated patients (n = 316) from four Autonomous Communities in Spain. Participants completed a battery of instruments to assess the following: buprenorphine dose adequacy; heroin dependence severity; psychological adjustment; and patient-desired adjustment of buprenorphine dose. Results Exploratory Factor Analysis identified four factors from the ODAS that together account for 85.4% of the total variance: “Heroin craving and use”; “Overmedication”; “Objective opiate withdrawal symptoms (OWS)” and ‘Subjective OWS’. Compared to patients with an “inadequate” B/N dose (ODAS), patients with “adequate” doses had less heroin use in the last week (0.01 vs. 0.40; t = −2.73; p < 0.01, 95% CI: −0.67, −0.10), less severe heroin dependence (2.20 vs. 5.26, t = −5.14, p < 0.001; 95% CI: −4.23, −1.88), less psychological distress (3.00 vs. 6.31, t = −4.37, p < 0.001; 95% CI: −4.80, −1.81), and greater satisfaction with their doses (42.1% vs. 13.6%, χ2 = 14.44, p < 0.01). Cronbach's alpha coefficient was 0.76 (0.81, 0.92, 0.94, and 0.93, respectively, for the four factor dimensions). Conclusion These findings support the validity and reliability of the ODAS as a tool to measure and assess buprenorphine dose adequacy in the context of an opioid dependency treatment program.
- Opioid dependence
- Substitution treatment